Value through Innovation27 July 2016

Page content

jump to main navigation jump to meta navigation

What is a lay summary?

To view this video in other translations click on the language below:
Chinese (simplified)
Chinese (traditional)
French
German
Italian
Japanese
Portuguese (Brazilian)
Spanish

Lay Summaries and Lay Summary Videos

  • CYLTEZO ® - Arthritis, Rheumatoid
    Clinical Study Number 1297.2
    Study Indication Arthritis, Rheumatoid
    Product CYLTEZO ®
    Generic Name Adalimumab-adbm
    Lab Code BI 695501
    Clinical Phase III
    Study Title

    Efficacy, safety and immunogenicity of BI 695501 versus adalimumab in patients with active rheumatoid arthritis: a randomized, double-blind, parallel arm, multiple dose, active comparator trial

    Study Document
    Lay summary 1297.2 english
  • CYLTEZO ® - Arthritis, Rheumatoid
    Clinical Study Number 1297.3
    Study Indication Arthritis, Rheumatoid
    Product CYLTEZO ®
    Generic Name Adalimumab-adbm
    Lab Code BI 695501
    Clinical Phase IIIb
    Study Title

    Long-term assessment of safety, efficacy, pharmacokinetics and immunogenicity of BI 695501 in patients with rheumatoid arthritis: an open-label extension trial for patients who have completed Trial 1297.2 and are eligible for long-term treatment with adalimumab (VOLTAIRE-RAext)

    Study Document
    Lay summary 1297.3 english
  • CYLTEZO ® - Psoriasis
    Clinical Study Number 1297.12
    Study Indication Psoriasis
    Product CYLTEZO ®
    Generic Name Adalimumab-adbm
    Lab Code BI 695501
    Clinical Phase III
    Study Title

    Efficacy, Safety, and Immunogenicity of BI 695501 versus Humira® in Patients with Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial

    Study Document
    Lay summary 1297.12 english
    Lay summary 1297.12 czech
    Lay summary 1297.12 estonian
    Lay summary 1297.12 german
    Lay summary 1297.12 polish
    Lay summary 1297.12 slovak
  • CYLTEZO ® - Psoriasis
    Clinical Study Number 1297.4
    Study Indication Psoriasis
    Product CYLTEZO ®
    Generic Name Adalimumab-adbm
    Lab Code
    Clinical Phase III
    Study Title

    BI 695501 versus Humira® in patients with active Crohn’s disease: a randomized, double-blind, multicenter, parallel group, exploratory trial comparing efficacy, endoscopic improvement, safety, and immunogenicity

    Study Document
    Lay summary 1297-0004 english

New selection